Related Experiment Video

Updated: Jan 27, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

9.1K

Serum platelet factor 4 is a promising predictor in newly diagnosed patients with multiple myeloma treated with

Ju Bai1, Jianli Wang1, Yun Yang1

  • 1a Department of Hematology , Second Affiliated Hospital, Xi'an Jiaotong University , Xi'an , People's Republic of China.

Hematology (Amsterdam, Netherlands)
|March 21, 2019
PubMed
Abstract

Insights

Serum platelet factor 4 (PF4) levels predict treatment response and survival in newly diagnosed multiple myeloma (MM). Lower PF4 indicates better outcomes with thalidomide and VAD regimens, suggesting its prognostic value.

Area of Science:

  • Hematology
  • Oncology
  • Biomarker Research

Background:

  • Platelet factor 4 (PF4) expression loss is common in multiple myeloma (MM).
  • The prognostic significance of serum PF4 levels in newly diagnosed MM remains unclear.
  • Previous research indicates PF4 loss in MM, but predictive value for treatment outcomes needs elucidation.

Purpose of the Study:

  • To evaluate serum PF4 as a prognostic factor for treatment response.
  • To assess the predictive value of serum PF4 for survival in MM patients.
  • To investigate the association of serum PF4 with treatment outcomes in MM patients receiving thalidomide and VAD.

Main Methods:

  • Serum samples from 122 MM patients were analyzed pre- and post-treatment.
  • Enzyme-linked immunosorbent assay (ELISA) was used for PF4 quantification.
  • Kaplan-Meier, log-rank tests, and Cox-regression models were employed for survival and multivariate analyses.

Main Results:

  • Lower serum PF4 concentrations correlated with better treatment response (complete remission, very good partial remission).
  • Serum PF4 levels showed significant associations with unfavorable clinical features like elevated β2-microglobulin, advanced ISS stage, del17p, and creatinine.
  • Low serum PF4 was an independent predictor of poor overall survival, alongside del17p and β2-microglobulin.

Conclusions:

  • Serum PF4 is a promising biomarker for predicting treatment response in MM.
  • Serum PF4 levels serve as a valuable prognostic factor for overall survival in MM patients.
  • The study suggests serum PF4 can guide treatment strategies for newly diagnosed MM patients receiving thalidomide and VAD.
Keywords:
Serum platelet factor 4multiple myelomaprognostic factorresponse

More Related Videos

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.5K
Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma07:53

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Published on: April 15, 2022

4.7K

Related Concept Videos

Dosage Regimen: Multiple Oral Dosage01:25

Dosage Regimen: Multiple Oral Dosage

Understanding how a drug's concentration fluctuates within the body over time is crucial in pharmacokinetics, particularly with multiple oral doses. A graphical representation of multiple oral dosages provides insight into these dynamics. Typical accumulation curves of a drug's concentration in the body reveal a sawtooth pattern, indicating periodic peaks and troughs correlating with each dose administration and the drug's subsequent elimination.The plasma concentration at any time during an...
250
Factors Affecting Protein-Drug Binding: Patient-Related Factors01:29

Factors Affecting Protein-Drug Binding: Patient-Related Factors

Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
316
Diagnosing Acidosis and Alkalosis01:24

Diagnosing Acidosis and Alkalosis

Diagnosing acid-base imbalances involves systematically analyzing arterial blood samples, focusing on three key measurements: pH, bicarbonate (HCO3−) concentration, and carbon dioxide partial pressure (PCO2). This analysis follows a four-step process that helps identify the imbalance's underlying cause and nature.
First, the pH level is assessed to determine whether the blood pH is normal (7.35–7.45), low (acidosis), or high (alkalosis).
Next, the PCO2  and...
1.2K
Drug Dosage Regimen: Overview01:15

Drug Dosage Regimen: Overview

A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
4.4K
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
178
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
165